StockData
Medifast Inc logo

Medifast Inc (MED) stock

MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 10/3056% below fair value
$12.54−0.43 (-3.32%)

Close on Nov 16, 2026Market cap $140.23MP/E –Yield 0.00%

Medifast r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $4.30M, down 6.5% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $4.60M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.30M-6.5%
FY2024Dec 31, 2024$4.60M0.0%
FY2023Dec 31, 2023$4.60M+2.2%
FY2022Dec 31, 2022$4.50M+2.3%
FY2021Dec 31, 2021$4.40M+57.1%
FY2020Dec 31, 2020$2.80M+3.7%
FY2019Dec 31, 2019$2.70M+22.7%
FY2018Dec 31, 2018$2.20M+46.7%
FY2017Dec 31, 2017$1.50M-25.0%
FY2016Dec 31, 2016$2.00M+11.1%
FY2015Dec 31, 2015$1.80M+38.5%
FY2014Dec 31, 2014$1.30M–

More Medifast figures

See a number that looks wrong?